AAAAAA

   
Results: 1-7 |
Results: 7
MORTALITY RISK PREDICTION OF SEPSIS - REPLY
Authors: BARRIERE SL LOWRY SF
Citation: Sl. Barriere et Sf. Lowry, MORTALITY RISK PREDICTION OF SEPSIS - REPLY, Critical care medicine, 24(1), 1996, pp. 181-181
AN OVERVIEW OF MORTALITY RISK PREDICTION IN SEPSIS
Authors: BARRIERE SL LOWRY SF
Citation: Sl. Barriere et Sf. Lowry, AN OVERVIEW OF MORTALITY RISK PREDICTION IN SEPSIS, Critical care medicine, 23(2), 1995, pp. 376-393
MORTALITY RISK PREDICTION IN SEPSIS - REPLY
Authors: BARRIERE SL LOWRY SF
Citation: Sl. Barriere et Sf. Lowry, MORTALITY RISK PREDICTION IN SEPSIS - REPLY, Critical care medicine, 23(10), 1995, pp. 1793-1794
PLASMA-CLEARANCE (CL) OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA) IN PATIENTS WITH SEPSIS SYNDROME
Authors: BLOEDOW DC PRIBBLE JP CATALANO MA FISHER CJ SCHENTAG JJ JARESKO GS BARRIERE SL
Citation: Dc. Bloedow et al., PLASMA-CLEARANCE (CL) OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA) IN PATIENTS WITH SEPSIS SYNDROME, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 196-196
EFFECTS OF RECOMBINANT INTERLEUKIN-1-RECEPTOR ANTAGONIST
Authors: BARRIERE SL PRIBBLE JP
Citation: Sl. Barriere et Jp. Pribble, EFFECTS OF RECOMBINANT INTERLEUKIN-1-RECEPTOR ANTAGONIST, American journal of hospital pharmacy, 51(9), 1994, pp. 1253-1257
ALTERNATIVE VIEWS ON THE EFFECTS OF RECOMBINANT INTERLEUKIN-1-RECEPTOR ANTAGONIST
Authors: BARRIERE SL PRIBBLE JP
Citation: Sl. Barriere et Jp. Pribble, ALTERNATIVE VIEWS ON THE EFFECTS OF RECOMBINANT INTERLEUKIN-1-RECEPTOR ANTAGONIST, American journal of hospital pharmacy, 51(21), 1994, pp. 2725-2727
REVIEW OF IN-VITRO ACTIVITY, PHARMACOKINETIC CHARACTERISTICS, SAFETY,AND CLINICAL EFFICACY OF CEFPROZIL, A NEW ORAL CEPHALOSPORIN
Authors: BARRIERE SL
Citation: Sl. Barriere, REVIEW OF IN-VITRO ACTIVITY, PHARMACOKINETIC CHARACTERISTICS, SAFETY,AND CLINICAL EFFICACY OF CEFPROZIL, A NEW ORAL CEPHALOSPORIN, The Annals of pharmacotherapy, 27(9), 1993, pp. 1082-1089
Risultati: 1-7 |